anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Soft tissue sarcomas (STS) are derived from mesenchymal cells, and can arise at any site. Retroperitoneal sarcomas (RPS) account for \~15% of STS, and patients have much worse survival outcomes than for extremity STS. Local (abdominal) recurrence of RPS is very common, due to the challenges of obtaining complete resection of these large masses that abut critical central compartment structures, such as the inferior vena cava and aorta. There is currently intense interest in using preoperative therapy to downsize/cytoreduce RPS and hopefully improve oncologic outcomes. Studies have shown that preoperative radiation does not cytoreduce these tumours. In this study, the potential of systemic therapy for cytoreduction will be examined.

The standard systemic therapy regimen for treatment of patients with STS remains Adriamycin/Ifosphamide, although side effects can be tolerated only by relatively young and fit patients. The use of this regimen preoperatively for extremity STS results in average response rates of about 30-40%, as judged by histologic assessment of the resected specimen. The international experience with preoperative chemotherapy for RPS is very limited, and there are no published reports.

Functional imaging may provide a more meaningful assessment of tumour response to systemic therapy. PET-MR is a newer modality that may hold promise in assessing solid tumour response and its potential utility is currently of rapidly growing interest. Conventional MRI can offer a more detailed assessment of tumour relationships to adjacent structures than can CT, particularly in STS. Integration of PET with MR has the potential to provide information about metabolic tumour volume (MTV) and to help guide surgical planning.There are no data available on the utility of PET-MR in evaluating tumour response to chemotherapy in STS.

At present, the role of chemotherapy as a preoperative treatment for retroperitoneal sarcoma (RPS) is undefined and controversial. The sarcoma group at Princess Margaret Cancer Centre (PMCC) has had some experience with this treatment paradigm, but like most sarcoma groups in Ontario, and Canada, has reserved preoperative chemotherapy for frankly unresectable and borderline resectable tumours for which downsizing would potentially render resection more feasible. At present, CT-scan imaging is performed after 2 cycles of chemotherapy, and if there is no frank progression of the cancer, chemotherapy is continued for another 3-4 cycles. By that point the tumour is smaller on CT scan in about 30% of patients. There are 2 main problems with this approach: 1)70% of the patients may have undergone 5-6 cycles of chemotherapy with no apparent benefit; and 2) there may be a metabolic response and associated benefit without a change in tumour size. The ability to reliably assess tumour response earlier on (i.e. after 1 cycle) would significantly influence the care of these patients as ineffective chemotherapy could be terminated after 1 cycle and the regimen could be modified, or surgery could happen right away before the window of resectability is lost.
Parents will be approached either prenatally for an impending delivery of ELBW newborn or within 16 hours of birth. 90 newborns will be randomized to receive early caffeine within 24 hours of life (the "study drug") and 90 newborns will receive a placebo. Either the early caffeine (the "study drug") or placebo will be continued throughout the first 15 days of life. Newborns in the early caffeine group will receive an IV bolus of 20mg/kg followed by IV or PO 5mg/kg daily for 14 days. The clinical team can choose to give PO caffeine if the newborn tolerates \>75% of fluid goals by feeds. The clinical and research teams will be blinded; neither will know whether the newborn is receiving early caffeine or placebo. The clinical team will be allowed to use open labeled caffeine as deemed medically necessary after 24 hours of receiving either the early caffeine or placebo. Often this clinical need would be at the time of extubation (peri-extubation) and comprises the "late" caffeine group, which is also the placebo group. Perinatal and postnatal clinical characteristics will be prospectively collected. Clinical team may choose to hold study drug if newborns are placed on high frequency ventilation or if they need sedation drips for surgical procedures. Two blood samples will be collected one at day 7 and one at day 14 for caffeine levels. Data safety monitoring committee will be review mortality and morbidity in each group on a quarterly basis or after recruitment of every 30 newborns whichever happens earlier.
A randomized double blind control trial. All patients undergoing upper abdominal, thoracic, gynecologic or orthopaedic surgeries at the Centre Hospitalier Universitaire de Kigali, Kigali, Rwanda will be invited to participate. Enrolled patients will receive subcutaneous ketamine (or placebo) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections at a dose of 1mg/kg. The primary outcome will be a reduction in mean Pain Scores using parametric statistical analysis to discriminate significance. Pain will be measured using an 11-point numerical rating scale. Secondary outcomes will be the presence of significant side effects. This trial is a partnership between the University of Saskatchewan and the National University of Rwanda with ethics approval from each institutions ethics board.
This is a multi-center, open-label and single arm study. At least 50 patients with moderate asthma receive Bronchial Thermoplasty for three times. Asthma Quality of Life Questionnaire (AQLQ), Asthma Control Questionnaire (ACQ), Frequency of mild asthma acute attack, PEF, FEV1, Emergency and Hospitalization are compared between before and after BT treatment.

The unified peak flow test meter will be provided to all subjects enrolled in this study. They will get a follow-up diary book before leaving hospital. In order to ensure the efficiency, all enrolled asthma patients are trained and tested by doctors and nurses from in-patient or out-patient department when they follow up, including how to use the PEF meter, how to read and record the data. As for the dosage of medication, all the medication uses are followed the doctor's advice, once the rescue medications were used, the times and dosages are mandatory to be recorded in the diary book by the patients themselves.
PURPOSE:To produce a drug preparation containing stabilized 2-O-higher alkyl- ascorbic acid or its derivative and useful as a preventive and remedy for circulatory function disorder, especially a drug for myocardial infarction by using a reducing compound as a component. CONSTITUTION:A reducing compound having reducing ene-diol group (e.g. isoascorbic acid) or a reducing compound having reducing thiol group (e.g. amino acid) is compounded to a 2-O-higher alkyl-ascorbic acid (2-O-A-VC) used as a main agent. The amount of the reducing compound is 0.001-20 pts.wt. per 1 pt.wt. of the 2-O-A-VC or its derivative. More preferably, a cyclodextrin is compounded to the preparation at a proper rate to obtain a stabilized preparation. The preparation is free from lowering of the content caused by decomposition, deterioration by dissolution, etc., and suitable as a drug for injection.
Letermovir administered either orally or intravenously within 28 days post-transplant, once daily through week 14 (approximately 100 days). Dosing will vary based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
Patients who suffer from sepsis typically experience acute lung injury (ALI). Extracellular vesicles (EVs) contain miRNAs, which are potentially involved in ALI. However, strategies to screen more effective EV-miRNAs as therapeutic targets are yet to be elucidated. In this study, functional EV-miRNAs were identified based on multiomics analysis of single-cell RNA sequencing of targeted organs and serum EV (sEV) miRNA profiles in patients with sepsis. The proportions of neutrophils and macrophages were increased significantly in the lungs of mice receiving sEVs from patients with sepsis compared with healthy controls. Macrophages released more EVs than neutrophils. MiR-125a-5p delivery by sEVs to lung macrophages inhibited Tnfaip3, while miR-221-3p delivery to lung neutrophils inhibited Fos. Macrophage membrane nanoparticles (MM NPs) loaded with an miR-125a-5p inhibitor or miR-221-3p mimic attenuated the response to lipopolysaccharide (LPS)-induced ALI. Transcriptome profiling revealed that EVs derived from LPS-stimulated bone marrow-derived macrophages (BMDMs) induced oxidative stress in neutrophils. Blocking toll-like receptor, CXCR2, or TNFα signaling in neutrophils attenuated the oxidative stress induced by LPS-stimulated BMDM-EVs. This study presents a novel method to screen functional EV-miRNAs and highlights the pivotal role of macrophage-derived EVs in ALI. MM NPs, as delivery systems of key sEV-miRNA mimics or inhibitors, alleviated cellular responses observed in sepsis-induced ALI. This strategy can be used to reduce septic organ damage, particularly lung damage, by targeting EVs.
PURPOSE:To obtain a skin beautifying agent having actions to suppress melanogenesis and dissipate pigmentation formed by the stimulation with ultraviolet rays, etc., and giving a skin cosmetic having excellent skin beautifying effect and the preventing and treating effect on the spots and freckles caused by sunburn, etc. CONSTITUTION:A skin beautifying agent composed of inostamycin of the formula (Me is methyl; Et is ethyl) and a skin cosmetic containing the compound. The compound of the formula can be separated from the supernatant of a cultivation product obtained by the culture of an actinomycete. The amount of compound of the formula to be compounded to the skin cosmetic is preferably 0.00001-10wt.%, especially 0.0001-5wt.%. This skin cosmetic includes quasi-drugs and medicines for external use, etc., as well as common skin cosmetics. It is used in various forms such as cream, milky lotion, face lotion, foundation, pack, lotion, gel, solution or stick according to the use.
Subjects randomized to this arm will receive statin therapy (simvastatin 40 mg) two days before surgery -- allowing three doses of simvastatin before incision -- and these will be continued until patients are either discharged from the hospital or have completed a 3-day postoperative course (6 days of simvastatin therapy), whichever occurs earlier. If patients are unable to take oral medications, the enteral route via nasogastric tube (at our institution, nasogastric tubes are routinely placed for both lumbar and thoracic instrumentation) will be used to deliver either placebo or the statin, as no parenteral form of this drug is currently available.
A cosmetic topical formulation and method are directed toward diminishing skin wrinkling and fine lines and improving skin tone. It contains a matrix metalloproteinase inhibitor, MMPI, e.g. batimastat or marimastat, and a natural estrogen, e.g., a true estrogen compound, such as 17-beta estradiol, or an estrogen-like steroid (such as various phytoestrogens found in herbal preparations). Exemplary phytoestrogens include triterpenoid glycosides. Certain compositions of this invention are useful for minimizing photodamage to skin, while in other embodiments, a composition according to this invention is useful to prevent or minimize the adverse effects on skin induced by cigarette smoking. The method of the invention involves administering the components such as in a dermal preparation.
PROBLEM TO BE SOLVED: To provide bedding capable of masking body odor of sweat, etc., without giving uncomfortable feeling to a user, by composing the bedding with a fiber material and impregnating perfume precursors. SOLUTION: Perfume precursors are to be decomposed by hydrolysis enzyme to produce perfume components and glucoside, glyceride, peptide derivatives, amino acid derivatives, phosphoric acid derivatives, etc., of perfume can be used. Either one or a blended plurality of those perfume precursors can be used. As a fiber material, synthetic fiber such as polyester and natural fiber such as cotton can be used. Perfume precursors and enzyme are impregnated into bedding without giving uncomfortable feeling by perfume to a user. When moisture by such as sweat is applied to bedding, microorganism starts to act at first to decompose the perfume precursors to discharge fragrance, thus, body odor from sweat, etc., can be masked. Further, the discharge amount of perfume can be controlled by impregnating enzyme to decompose perfume precursors into bedding.
Chitin is a poly saccharide, abundant in insects, fungi, crustaceans and other organisms, but not in mammals. Chitinases and chitinase like proteins (which have the ability to bind chitin without enzymatic activity) are members of the 18-glycosyl-hydrolase family. Their function and importance are still not clearly understood. However, several reports have linked the chitinase 3 like 1 protein with colitis and asthma. Furthermore, Johansen et al have reported elevated levels of chitinase 3 like 1 protein in patients with liver disease, mainly those with alcoholic liver disease (ALD) and fibrosis. This report consisted of 51 patients with ALD ,but only 16 and 17 patients with fatty liver and viral hepatitis respectively.

This study aims to evaluate the correlation of chitinase 3 like 1 protein with clinical parameters such as disease severity, reaction to treatment, portal hypertension (when measured) and prognosis.

\*\*\*Study design:

a. Subjects i.The study will include patients with liver disease followed at the liver unit, Hadassah Medical Center, Jerusalem. b. Planned number i.The study is planned to include 200 volunteers. c. Inclusion criteria i.Patients with liver disease followed at the liver unit at Hadassah Medical Center. ii.Patients who have given their informed consent for participation in the study. d. Exclusion criteria i.Age\<18y. ii.Pregnancy iii.Patients with other conditions associated with elevated chitinase 3 like 1 protein (such as asthma and rheumatoid arthritis). e. Chitinase 3 like-1 protein levels will be measured by a commercially available kit (Human Chitinase 3-like 1 Quantikine ELISA Kit, catalogue number - DC3L1, Biotest LTD). f. Stopping/modifying criteria i.At subjects' request. g. Trial entry and enrollment i.A consecutive cohort will be recruited form amongst the patients followed at the liver unit in Hadassah medical center. Jerusalem Israel. ii.Consenting patients will have a blood test drawn for chitinase 3 like 1 protein levels. iii.Clinical details of each patient will be obtained form the liver unit. iv.In addition to the routine follow up at the liver unit, follow up will be performed at 1,2 and 5 years. h. Statistical considerations i.Subjects will be grouped according to their clinical properties (disease, treatment, severity, portal hypertension) ii.Chitinase 3 like 1 protein levels will be compared between each group. F. Informed consent i.Each subject will be enrolled and enter the study only after giving an informed consent. G. Adherence to study eligibility i.The study will be conducted in accordance with good clinical practice (GCP) guidelines, and the study protocol. H. Safeguarding of documents i.The privacy of the subjects and all confidentiality issues will be handled in accordance with applicable law and guidelines of the institution and the Helsinki Committee, the Israeli ministry of health, or the other appropriate regulatory authorities.
.Informed consent will be taken from all the patients who meet the inclusion and exclusion criteria and then will be randomized into one of the two study arms (Arm 1: will undergo wound closure with staples and Arm 2 wound closure with subcuticular prolene suture).

before the start of surgery. The primary investigator will open the sealed envelopes provided by the Indus Hospital Research Center's Clinical Research Unit (CRU) that provides the study arm allocation. The envelopes will follow the SNOSE protocol i.e. they will be sequentially numbered, opaque sealed envelopes. Before opening the envelope, the primary investigator will write the patient's medical record number, date and will sign the envelope. The envelope will contain carbon paper which will transfer the data allocation paper inside.
Obesity is a prevalent disease, but effective treatment options remain limited. Agonists of the alpha-7 nicotinic acetylcholine receptor (α7nAChR) promote negative energy balance in mice, but these effects are not well-studied in rats. We tested the hypothesis that central administration of the α7nAChR agonist PHA-543613 (PHA) would decrease food intake and body weight in adult male Sprague Dawley rats. Intracerebroventricular (ICV) PHA administration in chow-fed rats produced a suppression of energy intake and weight gain over 24 h. Next, to evaluate effects of ICV PHA on palatable food intake, rats were maintained on a choice diet of rodent chow and 45 % high fat diet (HFD); under these conditions, ICV PHA produced no significant changes in energy intake from either food, or body weight gain, in the 24 h post-injection. However, when given a choice of chow or a higher-fat 60 % HFD, ICV PHA reduced intake of 60 % HFD, but not chow; body weight gain was also suppressed. Further experiments evaluating conditioned taste avoidance (CTA) and pica in response to ICV PHA suggested that the suppressive food intake and body weight effects after ICV injection of PHA were not due to nausea/malaise. Finally, an operant conditioning study showed that responding on a progressive ratio schedule of reinforcement for high-fat food pellets decreased after ICV PHA. Collectively, these studies show that PHA reduces energy intake under some but not all dietary conditions. Importantly, central PHA decreases both food intake as well as motivation for highly palatable, energy dense foods in rats without inducing nausea/malaise, suggesting that the α7nAChR could be a viable target for developing treatments for obesity.
Altered shape of the proximal femur (cam morphology) or acetabulum (pincer morphology) is indicative of femoroacetabular impingement, which can result in hip pain and osteoarthritis of the hip. As mechanical load during growth affects the resulting bone shape, there is strong evidence in males that cam morphology develops during skeletal growth while physes are open, rather than as an adaptation after growth plates are closed (skeletal maturity). This adaptation is particularly evident in athletes who participate at elite levels prior to skeletal maturity. The research providing this evidence, however, has primarily focused on male athletes. Despite the lack of inclusion in the research, females consistently comprise two thirds of the clinical and surgical populations with structural hip pain or pathology. Knowledge gained from male-dominated cohorts may not appropriately transfer to female athletes, especially at the hip. This perspectives article briefly reviews differences between females and males in femoral and acetabular structure, hormones, timing of puberty/maturation, hypermobility, activity level and movement control-factors which affect hip structure development and loading. Without female-focused research, the application of research findings from male athletes to female athletes may lead to ineffective or even inappropriate recommendations and treatments. Thus, there is a critical need for investment in research to promote life-long hip health for females.
The study will be conducted in two phases, beginning with a pilot (Phase I). The aim of the pilot will be to develop and test four types of housing modifications in both modern houses (those with brick or stone walls) and traditionally constructed houses (those with mud walls). The housing modifications will include: (1) full house screening (eaves and windows), (2) partial house screening (eaves or ceiling), (3) eave tubes, and (4) eave ribbons. Community input will be sought during the development of the housing prototypes.

In the pilot, all 4 interventions will be implemented in both modern and traditional houses, plus a control arm in each group. All households will have access to PBO LLINs. Community input will be sought during the development of the housing prototypes. The pilot will include 10 arms in total, each consisting of 20 households, equal to 200 households (160 in the intervention and 40 in the control arm) in total. The feasibility and effectiveness of the interventions will be assessed through a qualitative study (FGDs and interviews), evaluation of the costs and implementation of the interventions, and entomology surveys (using CDC light traps). One to two housing interventions will be selected for Phase II following the review and discussion of the pilot results with the trial steering committee.

Phase II will include a cluster-randomised trial. A cluster will be defined as a village (or segment of a village consisting of \~100 households). In the cluster-randomised trial, up to 2 interventions vs 1 control arm will be assessed in 20 clusters per arm (60 clusters total). The clusters will be non-contiguous, with a buffer zone of 300-500m. All households in the selected clusters will have PBO LLINs; households in intervention clusters will also receive the specified housing modifications. The impact of the interventions will be assessed through a cohort study, cross-sectional community surveys, entomology surveillance, a qualitative study, and an economic evaluation. The primary outcome of the trial will be clinical malaria incidence in children aged \< 60 months as measured in the cohort study.
The invention relates to ingredients involved in children heat-phlegm clearing and liver nourishing dietotherapy as well as a manufacturing method of the diet and provides a dietotherapy method combining practical experiences with scientific pharmacological analysis. The composition comprises bupleurum, glycyrrhiza, nodakenin, rhizome chuanxiong, radix angelicae pubescentis, poria cocos, live turtle, crystal sugar, rice wine, lard, sesame oil and Cicada Slough. The head of the live turtle is cut off. Blood is dropped over. Then, the turtle without head is put in cold water to be boiled and taken out. A black membrane is scrapped to clean the boiled turtle. A cross edge is incised on the abdomen of the turtle. Viscera and back shell are eliminated. Then, the turtle is cut into blocks which are cleaned with cold water. The turtle is put in boiling water to be scalded and taken out. The lard is added. Then, the turtle, the crystal sugar and the rice wine are added. Other materials are also added. The materials are put in a sealed vacuum tank. With the ingredients adopted, the dietotherapy has the effects of clearing heat and removing phlegm, inducing resuscitation, relieving uneasiness, soothing liver to subside endogenous wind, eliminating lump in breast, soothing wind and clearing liver and nourishing liver and dispelling nephelium.
Participants randomized into the Standard BP Control arm will have a goal of home SBP \<135mmHg. The Standard BP protocol is designed to achieve a home SBP of 130-134 mmHg in as many participants as possible. Following the randomization visit, medication dose titration or addition of another drug is indicated if home SBP ≥135 mmHg. Monthly visits will continue in the Standard Group when home SBP ≥155 mmHg. Down titration (a reduction of the dose or number of antihypertensive drugs) should be carried out if the home SBP is \<125 mmHg.